Press Releases

Completion of the Transaction and admission to trading on the London Stock Exchange

Click here to download full announcement 12 April 2017 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM...

View details

Proposed Collaboration and Securing of Certain U.S. Commercial Rights to Tudorza® and Duaklir® from AstraZeneca

Click here to download the full announcement 17 March 2017 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR...

View details

Interim Results for the Six Months Ended 30 June 2016

Click here to download the full 2016 interim results statement – Strong NIOX® sales growth; respiratory pipeline progressing – – Unexpected phase III allergy results; Spring 2017 house dust mite results will inform allergy approach...

View details

Notice of Interim Results

Oxford, UK – 15 July 2016: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a specialty biopharmaceutical company focused on allergy and respiratory medicine, will announce its interim results for the six months ended...

View details

Circassia Announces Top-Line Results from Cat Allergy Phase III Study

Click here to download the full press release – Primary endpoint not achieved – – Treatment groups had dramatically reduced Combined Score and symptoms – – Powerful placebo response eliminated ability to identify treatment effect...

View details

Circassia Initiates Grass Allergy Immunotherapy Registration Study

Click here to download full press release – Second allergy programme moves into final phase of clinical testing – – Lead programme targeting cat allergy on track to report phase III results Q2 2016 –...

View details

Preliminary Results for the Year Ended 31 December 2015

Click here to download the full 2015 preliminary results statement – Positioned to deliver – – Cat allergy phase III study on track to report Q2 2016 – – Acquisitions validated; strong NIOX® sales growth...

View details

Notice of Preliminary Results

Oxford, UK – 7 March 2016: Circassia Pharmaceuticals plc (LSE: CIR), a specialty biopharmaceutical company focused on allergy and respiratory medicine, will announce its preliminary results for the year ended 31 December 2015 on Friday...

View details

Circassia Announces Positive Outcome of European Decentralised Procedure for Approval of Its Fluticasone Propionate Equivalent of GSK’s FLIXOTIDE® pMDI

Click here to download the full press release – Product approvable in all reference product strengths – – Successful application based on in vitro demonstration of therapeutic equivalence – Oxford, UK – 24 November 2015:...

View details

Circassia Business Update

Click here to download the full business update — Good clinical progress across whole allergy and respiratory portfolio — — Strong commercial progress with significant NIOX® sales growth — — Robust balance sheet to fund...

View details